EUCTR2004-004577-28-GB进行中（未招募）1 期
Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgaris
EO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S )0 个研究点目标入组 0 人开始时间: 2005年3月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Clinical diagnosis of psoriasis vulgaris amenable to treatment with a maximum of 100g of topical medication per week, involving arms and/or trunk and/or legs.
- •2. An investigators’ global assessment of moderate, severe or very severe disease.
- •3. A minimum PASI score for extent of 2 in at least one body region (i.e. psoriasis affecting at least 10% of arms and/or 10% of trunk and/or 10% of legs).
- •4. Attending hospital outpatient clinic, the private practice of a dermatologist or general practice for psoriasis treatment.
- •5. Aged 18 years or above.
- •6. Either sex.
- •7. Any ethnic origin.
- •8. Following receipt of verbal and written information about the study, the patient must provide signed and dated informed consent before any trial related activity is carried out.
- •9. Females of child-bearing potential must have a negative result for a urine pregnancy test before randomisation and must agree to use an adequate method of contraception during the study.
- •10. Patients fulfilling national requirement/law for participation in this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Requirement for treatment of more than 30% of body surface area with study medication.
- •2. Current diagnosis of erythrodermic, exfoliative, pustular or guttate psoriasis.
- •3. Use of systemic treatments which may have an effect on psoriasis (apart from biologic therapies) within 4 weeks prior to visit 1. Such treatments are corticosteroids, retinoids, hydroxycarbamide, azathioprine, methotrexate, ciclosporin and other immunosuppressants.
- •4. Use of biologic therapies which may have an effect on psoriasis within 6 months prior to visit 1.
- •5. PUVA or Grenz ray therapy within 4 weeks prior to visit 1.
- •6. UVB therapy within 2 weeks prior to visit 1.
- •7. Planned use of topical treatment for psoriasis of trunk or limbs besides study medication (including the use of emollient) during the study (no washout period before randomisation is necessary).
- •8. Planned initiation of or changes to non-antipsoriatic concomitant medication that could affect psoriasis (e.g. beta-blockers, lithium) during the study.
- •9. Planned exposure to sun during the study, that may affect the psoriasis.
- •10. Known or suspected hypersensitivity to any of the constituents of the study medications.
- •11. Known disorders of calcium metabolism associated with hypercalcaemia.
- •12. Patients with any of the following conditions also present on psoriatic areas of the trunk or limbs: viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis or syphilis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers or wounds.
- •13. Other inflammatory skin diseases that may confound the evaluation of the psoriasis.
- •14. Females who are pregnant, breast feeding or who wish to become pregnant during the study period.
- •15. Patients who have received treatment with an investigational product within 4 weeks prior to visit 1 or are currently participating in another clinical trial.
- •16. Previous enrolment into this study.
- •17. Patient known or suspected of being unable to comply with the study protocol for the 12-week period, e.g. due to alcoholism, drug dependence or psychotic state.
- •18. Severe renal insufficiency or severe hepatic disorders.
研究者
相似试验
进行中（未招募）
1 期
Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgarisPsoriasis vulgaris of the trunk and/or limbs with at least 10% involvement of arms and/or 10% of legs and/or 10% of trunkMedDRA version: 7.0Level: LLTClassification code 10050576EUCTR2004-004577-28-ESFARMACUSI S.A.
进行中（未招募）
不适用
Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgarisPsoriasis vulgaris of the trunk and/or limbs with at least 10% involvement of arms and/or 10% of legs and/or 10% of trunkMedDRA version: 7.0Level: LLTClassification code 10050576EUCTR2004-004577-28-BEEO Pharma A/S1,032
进行中（未招募）
不适用
Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgarisEUCTR2004-004577-28-DEEO Pharma A/S1,020
尚未招募
不适用
Comparison of two topical vitamin D analogues in form of ointments in combination with phototherapy in treatment of psoriasisCTRI/2022/06/043333Kamal Aggarwal
已完成
3 期
The effect of calcitriol ointment on skin wartsSkin warts.Viral wartsIRCT20170818035762N2Mazandaran University of Medical Sciences56